Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia

Documenti analoghi

• Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
  di: Pavan Vaddady, et al.
  Pubblicazione: (2024)
• KMT2C/D mutations in newly diagnosed acute myeloid leukaemia: Clinical features, genetic co‐occurrences and prognostic significance
  di: Wenting Wang, et al.
  Pubblicazione: (2025)
• First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
  di: Rupa Narayan, et al.
  Pubblicazione: (2024)
• Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• Low methylthioadenosine phosphorylase expression is associated with worse survival in patients with acute myeloid leukaemia
  di: Yiyu Xiao, et al.
  Pubblicazione: (2024)